Twelve-day quintuple regime containing four antibiotics as a rescue therapy for Helicobacter pylori eradication in the central region of Portugal

Revista Española De Enfermedades Digestivas : Organo Oficial De La Sociedad Española De Patología Digestiva
Diogo BranquinhoLuís Tomé

Abstract

Helicobacter pylori eradication rates with standard triple therapy in many countries are clinically unacceptable. Fluoroquinolone resistance is increasing and jeopardizing second-line regimens. There is a growing need for an effective strategy in patients who failed previous therapies. This is a single-center, non-randomized clinical study conducted in the central region of Portugal. Sixty-four patients were included with a positive 13C-urea breath test (UBT) or histology for H. pylori, and at least one failed eradication attempt. The patient cohort included 71.7% of females with a median of age of 52 (range 23-87). They were treated with a twelve-day regimen consisting of a proton-pump inhibitor (PPI) bid, amoxicillin at 1,000 mg 12/12 h and levofloxacin at 500 mg bid during the first seven days, followed by PPI bid, clarithromycin at 500 mg 12/12h and either tinidazole or metronidazole at 500 mg bid/tid for five days. Eradication was assessed by UBT. The local Ethics Committee approved this study. Eradication therapy was prescribed due to dyspepsia (66.7%), peptic ulcer (10%) and thrombocytopenia (8.3%). The median number of failed therapies was one (range 1-4). The eradication rate was 64.6% according to an intention-to-trea...Continue Reading

References

Jun 2, 2007·Alimentary Pharmacology & Therapeutics·A ZulloD Vaira
Apr 20, 2012·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·A CosmeL Bujanda
Mar 7, 2013·The Journal of Antimicrobial Chemotherapy·Nicole WueppenhorstErik-Oliver Glocker
Mar 26, 2013·European Journal of Internal Medicine·Panagiotis PapagiannakisMichael D Diamantidis
Jun 12, 2013·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·David Y GrahamMing-Shiang Wu
Jul 19, 2013·European Journal of Gastroenterology & Hepatology·Michael SelgradPeter Malfertheiner
Jun 4, 2014·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·N AlmeidaC Sofia
Dec 17, 2014·International Journal of Antimicrobial Agents·Trung Nam PhanBianca Paglietti
Jan 17, 2015·World Journal of Gastroenterology : WJG·Fariborz Mansour-GhanaeiSeyed Mohammad Seyed Saadat
May 7, 2015·BioMed Research International·Toshihiro Nishizawa, Hidekazu Suzuki
Sep 29, 2015·World Journal of Methodology·Reza GhotaslouYalda Mohammadzadeh Asl
Feb 6, 2016·Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·Zhiqiang SongYan Xue
Feb 7, 2016·Clinics and Research in Hepatology and Gastroenterology·Nelly MullerJean-Charles Delchier
Jun 28, 2016·Gastroenterología y hepatología·Javier P GisbertAdrián G McNicholl
Nov 2, 2016·Gut·P MalfertheinerUNKNOWN European Helicobacter and Microbiota Study Group and Consensus panel

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.